Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : BioNTech to Report First Quarter 2021 Financial Results and Operational Update on May 10, 2021

05/04/2021 | 07:02am EDT
   Mainz, Germany, May 4, 2021 (GLOBE NEWSWIRE) -- BioNTech SE 
https://www.globenewswire.com/Tracker?data=wY9Uom0sCgV6RzwZEcQDbOnIRpbdCMjMdWm2fR51x-d2NGBfsVLk4op-iqlRc6YYPHN7bdnA56bNwR-pLsHnCA== 
(Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial 
results for the first quarter 2021 on Monday, May 10(th) , 2021. 
BioNTech invites investors and the general public to join a conference 
call and webcast with investment analysts on the same day at 8.00 a.m. 
EDT (2.00 p.m. CEST) to report its financial results and provide a 
corporate update for the first quarter 2021. 
 
   The slide presentation and audio of the webcast will be available via 
this li 
https://www.globenewswire.com/Tracker?data=gyt3pq6KqK4IHtSWB_dZRqfSe4zVPV-2w5VNsgnCDb4MSXxihUzou9dzxoDk1ISsaoGPP3J6gWoOSBZ2tBNOuBXbK-9uLi_TdICK3oP_4Tc= 
nk 
https://www.globenewswire.com/Tracker?data=tgdpNFtRhPQcMn8h53EPJMs0q8L6MJPOCzZnA4Rv_16SbchJGmncydV_dD4aageF7WUKaMkJ3b_7Qklkb1n9w-QnkQp5gFkjcrDVrKrrV5Y= 
. 
 
   To participate in the conference call, please dial the following numbers 
ten minutes prior to the start and provide the Conference ID: 
 
 
 
 
United States international:               +1 646 741 3167 
United States domestic (toll-free):        +1 877 870 9135 
Germany:                              +49 (0) 692 2222 625 
Conference ID:                                     8724098 
 
 
   Participants may also access the slides and the webcast of the 
conference call via the "Events & Presentations" page of the Investor 
Relations section of the Company's website at https://biontech.de/. A 
replay of the webcast will be available shortly after the conclusion of 
the call and archived on the Company's website for 30 days following the 
call. 
 
   About BioNTech 
 
   Biopharmaceutical New Technologies is a next generation immunotherapy 
company pioneering novel therapies for cancer and other serious 
diseases. The Company exploits a wide array of computational discovery 
and therapeutic drug platforms for the rapid development of novel 
biopharmaceuticals. Its broad portfolio of oncology product candidates 
includes individualized and off-the-shelf mRNA-based therapies, 
innovative chimeric antigen receptor T cells, bi-specific checkpoint 
immuno-modulators, targeted cancer antibodies and small molecules. Based 
on its deep expertise in mRNA vaccine development and in-house 
manufacturing capabilities, BioNTech and its collaborators are 
developing multiple mRNA vaccine candidates for a range of infectious 
diseases alongside its diverse oncology pipeline. BioNTech has 
established a broad set of relationships with multiple global 
pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal 
Health, Genentech, a member of the Roche Group, Regeneron, Genevant, 
Fosun Pharma, and Pfizer. 
 
   For more information, please visit www.BioNTech.de. 
 
   BioNTech Contacts 
 
   Investor Relations 
 
   Sylke Maas, Ph.D. 
 
   +49 (0)6131 9084 1074 
 
   Investors@biontech.de 
https://www.globenewswire.com/Tracker?data=fe6NDpEsQLEAlda1CHlJLBZ54tlL0nxmcs1xK6LOOVDxqcyBzYzIpYVH2q5M9fp0wSqguaZD6gD87vT8tjK1XAucsLAXu-QyZrPmBPe4bqw= 
 
 
   Media Relations 
 
   Jasmina Alatovic 
 
   +49 (0)6131 9084 1513 
 
   Media@biontech.de 
https://www.globenewswire.com/Tracker?data=g0O_n_PsO3okiGKVM-PE6q6hZ1-vkWn7LUsJWTJiGN2YwmOljGGq_kSq4zJ5QHX13E2TLY8JhlfAzS9En8Ws81egj3W9e7C3VlNHC94XDiY= 
 
 
 
 
 

(END) Dow Jones Newswires

May 04, 2021 07:02 ET (11:02 GMT)

All news about BIONTECH SE
01:48pEU Tepid on Biden Call to Waive Intellectual Property Rights for Covid-19 Vac..
DJ
09:27aPFIZER  : EU pens contract for further 1.8 billion Pfizer shots
AQ
05/07Correction to Impact of U.S. Support for Patent Waiver on Vaccine Makers Arti..
DJ
05/07Health Care Up On Cyclical Bias -- Health Care Roundup
DJ
05/07ASTRAZENECA PHARMA INDIA  : Key EU countries rebuff Biden on sharing COVID vacci..
RE
05/07Pfizer Lifts Covid-19 Vaccine Production Targets For 2021, 2022
DJ
05/07MARKET CHATTER : WHO's Director General Calls for Countries to Support Waiving C..
MT
05/07U.S. Support for Patent Waiver Unlikely to Cost Covid-19 Vaccine Makers in Sh..
DJ
05/07U.S. CDC panel to vote on using Pfizer COVID-19 shot in adolescents
RE
05/07Pfizer, BioNTech file for full U.S. approval of vaccine
RE
More news
Financials
Sales 2021 9 519 M 11 577 M 11 577 M
Net income 2021 5 747 M 6 989 M 6 989 M
Net cash 2021 6 515 M 7 924 M 7 924 M
P/E ratio 2021 6,78x
Yield 2021 -
Capitalization 36 481 M 44 370 M 44 368 M
EV / Sales 2021 3,15x
EV / Sales 2022 4,18x
Nbr of Employees 1 941
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 111,35 €
Last Close Price 151,05 €
Spread / Highest target 17,5%
Spread / Average Target -26,3%
Spread / Lowest Target -41,3%
EPS Revisions
Managers and Directors
NameTitle
Ugur Sahin Chief Executive Officer
Sierk Pötting Chief Operating & Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE125.36%44 370
GILEAD SCIENCES, INC.14.21%83 778
VERTEX PHARMACEUTICALS-9.03%55 659
WUXI APPTEC CO., LTD.6.21%54 226
REGENERON PHARMACEUTICALS3.22%51 442
BEIGENE, LTD.20.74%28 740